ATE389417T1 - Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen - Google Patents

Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen

Info

Publication number
ATE389417T1
ATE389417T1 AT98912149T AT98912149T ATE389417T1 AT E389417 T1 ATE389417 T1 AT E389417T1 AT 98912149 T AT98912149 T AT 98912149T AT 98912149 T AT98912149 T AT 98912149T AT E389417 T1 ATE389417 T1 AT E389417T1
Authority
AT
Austria
Prior art keywords
compositions
methods
inflammatory bowel
bowel disease
treating inflammatory
Prior art date
Application number
AT98912149T
Other languages
English (en)
Inventor
Thomas Julius Borody
Original Assignee
Borody Thomas J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed by Borody Thomas J filed Critical Borody Thomas J
Application granted granted Critical
Publication of ATE389417T1 publication Critical patent/ATE389417T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98912149T 1997-04-01 1998-04-01 Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen ATE389417T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease

Publications (1)

Publication Number Publication Date
ATE389417T1 true ATE389417T1 (de) 2008-04-15

Family

ID=25645389

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98912149T ATE389417T1 (de) 1997-04-01 1998-04-01 Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen

Country Status (16)

Country Link
US (1) US6277836B1 (de)
EP (1) EP0971735B1 (de)
JP (3) JP2001524951A (de)
AR (1) AR012304A1 (de)
AT (1) ATE389417T1 (de)
CA (1) CA2285923C (de)
CY (1) CY1109783T1 (de)
DE (1) DE69839261T2 (de)
DK (1) DK0971735T3 (de)
ES (1) ES2303351T3 (de)
IL (1) IL132145A (de)
NO (1) NO325947B1 (de)
NZ (1) NZ500696A (de)
PT (1) PT971735E (de)
SI (1) SI0971735T1 (de)
WO (1) WO1998043667A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
AU764681C (en) * 1999-02-12 2005-07-07 Washington University Stimulating neutrophil function to treat inflammatory bowel disease
ATE285821T1 (de) * 1999-10-08 2005-01-15 Affinium Pharm Inc Fab i inhibitoren
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
BR0109544A (pt) * 2000-03-28 2003-06-10 Biochemie Gmbh Partìculas granuladas com sabor ocultado
WO2002018324A2 (en) * 2000-08-29 2002-03-07 Nobex Corporation Immunoregulatory compounds, derivatives thereof and their use
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
EP1575951B1 (de) 2002-12-06 2014-06-25 Debiopharm International SA Heterozyclische verbindungen, verfahren zu deren herstellung und ihre verwendung als heilmittel
DE602004016831D1 (de) 2003-03-17 2008-11-13 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
WO2005072113A2 (en) 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
CA2555304C (en) 2004-02-06 2016-06-28 Nicolas Peter Shortis Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
EP2848614A3 (de) 2004-06-04 2015-07-29 Debiopharm International SA Acrylamidderivate und ihre Verwendung als Antibiotika
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
WO2007025146A2 (en) * 2005-08-24 2007-03-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture and use thereof
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP1973902A2 (de) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamidverbindungen als fabi-inhibitoren und antibakterielle mittel
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
EP2687533B1 (de) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamidderivate als FAB-I-Hemmer
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
WO2009047801A1 (en) * 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
WO2009064953A1 (en) * 2007-11-15 2009-05-22 Enanta Pharmaceuticals, Inc. Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
PT2247291T (pt) * 2008-02-08 2019-02-01 Red Hill Biopharma Ltd Métodos e composições para tratamento de doença inflamatória do intestino
EP2280713A1 (de) * 2008-05-01 2011-02-09 The Procter & Gamble Company Verfahren und kits zur behandlung von entzündlichen darmerkrankungen
US20110082120A1 (en) * 2009-10-05 2011-04-07 Milne Jill C Substituted thioacetic acid salicylate derivatives and their uses
PT2493471T (pt) 2009-10-26 2020-01-09 Borody Thomas J Nova terapia de combinação entérica
EP2563117B1 (de) 2010-04-26 2018-02-21 Salix Pharmaceuticals, Ltd. Formulierungen aus und verwendungen von 2-hydroxy-5-phenylazobenzoesäurederivaten zur behandlung männlicher patienten
CN103338768B (zh) 2010-12-13 2019-04-19 萨利克斯药品有限公司 胃和结肠的配制剂及其制备和使用方法
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
SI2861608T1 (sl) 2012-06-19 2019-08-30 Debiopharm International Sa Derivati predzdravila (E)-N-metil-N-((3-metilbenzofuran-2-IL)metil)- 3-(7-okso-5,6,7,8-tetrahidro-1 ,8-nafthiridin-3-il)akrilamid
HUE043852T2 (hu) 2012-07-27 2019-09-30 Redhill Biopharma Ltd A vastagbél kiürítésére szolgáló készítmények és a készítmények elõállítási módszerei
EP3145510B8 (de) * 2014-05-22 2021-10-27 Kuenstner, John, Todd Behandlung von krankheiten mittels kombination aus ultravioletter blutbestrahlung und antibiotika
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
LT3923914T (lt) 2019-02-14 2023-07-25 Debiopharm International S.A. Afabicino kompozicija, jos gamybos būdas
CN113939306B (zh) 2019-06-14 2024-07-19 德彪药业国际股份公司 用于治疗涉及生物膜的细菌感染的药物及其用途
WO2022003421A2 (en) 2020-06-30 2022-01-06 Redhill Biopharma Ltd. Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
EP0971735A1 (de) 2000-01-19
IL132145A (en) 2005-11-20
WO1998043667A1 (en) 1998-10-08
NO325947B1 (no) 2008-08-25
NO994778L (no) 1999-11-30
NZ500696A (en) 2002-05-31
DE69839261D1 (de) 2008-04-30
DE69839261T2 (de) 2009-03-26
CA2285923A1 (en) 1998-10-08
ES2303351T3 (es) 2008-08-01
US6277836B1 (en) 2001-08-21
CY1109783T1 (el) 2013-09-04
JP2001524951A (ja) 2001-12-04
EP0971735B1 (de) 2008-03-19
EP0971735A4 (de) 2004-02-25
JP2008024713A (ja) 2008-02-07
CA2285923C (en) 2013-03-12
IL132145A0 (en) 2001-03-19
SI0971735T1 (sl) 2008-08-31
AR012304A1 (es) 2000-10-18
JP2012126736A (ja) 2012-07-05
NO994778D0 (no) 1999-09-30
PT971735E (pt) 2008-06-02
DK0971735T3 (da) 2008-07-07

Similar Documents

Publication Publication Date Title
ATE389417T1 (de) Verfahren und zusammensetzungen zur behandlung entzündlicher darmerkrankungen
ATE241977T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
DE69820997D1 (de) Zusammensetzungen und verfahren zur behandlung des erhöhten augenindruckes
DE60003250D1 (de) Reinigungszusammensetzungen und Verfahren zur Reinigung
DE69834256D1 (de) Verfahren und zusammensetzung zur behandlung von verzögerten allergischen reaktionen und entzündungskrankheiten
DE69519235D1 (de) Hämorrhoidenzusammensetzungen und verfahren zur verwendung
ATE477270T1 (de) Verfahren und zusammensetzungen zur prävention und behandlung von anämie
ATE282591T1 (de) Thioharnstoffverbindungen, zusammensetzungen sowie verfahren zur behandlung oder verhütung von entzündlichen erkrankungen und atherosklerose
DE69836200D1 (de) Implantat Material und Verfahren zu seiner Herstellung
DE60042184D1 (de) Verfahren und Zusammensetzung zur Entschichtung von Photoresist
EP1014995A4 (de) Zusammensetzungen und verfahren zur verhütung von restenosis nach wiedergefässbildung
DE60018635D1 (de) Monofilament und Verfahren zu seiner Herstellung
EP1565230A4 (de) Materialzusammensetzungen und verwandtesysteme und verfahren zur behandlung von herzerkrankungen
ATE288278T1 (de) Verfahren und zusammensetzungen zur peptidsynthese
DE69714828D1 (de) Verfahren zur Behandlung von Abfallstoffen
ATE271598T1 (de) Desinfektionszusammensetzungen und verfahren
DE69822873D1 (de) Zusammensetzungen und verfahren zur gewichtsverringerung
DE69519577D1 (de) Prednisolonmetasulfobenzoatzusammensetzung zur behandlung von entzündungserkrankung des darmes
DE69909355D1 (de) Verbundene Gegenstände und Verfahren zum Herstellen solcher verbundener Gegenstände
EP1109548A4 (de) Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole
EP0883674A4 (de) Desinfizierende zusammensetzungen und verfahren zur desinfektion von oberflachen
DE69732470D1 (de) Abbaubares Monofilament und Verfahren zu seiner Herstellung
ATE415163T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE69924489D1 (de) Getreide-beta-glukanzusammensetzungen und verfahren
DE69919254D1 (de) Wasserabsorbierendes Mittel und Verfahren zu seiner Herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0971735

Country of ref document: EP